Benzinga cites a USD 544.00 target for Vertex Pharmaceuticals stock

Published on 10/26/2026 at 17:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vertex reports third-quarter results November 2 after the close. Vertex Pharmaceuticals stock costs EUR 458.85 on October 26, 2026, while Nasdaq shows USD 512.00.

Analyst target and reporting date

Benzinga listed a USD 544.00 consensus target from 27 analysts on October 26, 2026.
Vertex Pharmaceuticals reports third-quarter results on November 2, 2026, after the close.
Vertex Pharmaceuticals stock costs EUR 458.85 at Lang & Schwarz on October 26, 2026 at 5:16 p.m. CEST, while Nasdaq quoted USD 512.00.
Second-quarter revenue reached USD 3.33 billion, up 12.50 percent year over year.

Vertex Pharma, US92532F1003, Illustration mit AI erstellt.

Vertex Pharmaceuticals stock is tied to a USD 544.00 consensus target from 27 analysts, according to Benzinga on October 26, 2026. Against the USD 512.00 Nasdaq quote at 12:27 p.m. ET, the target is 6.25 percent above the price. Vertex Pharmaceuticals was trading at EUR 458.85 at Lang & Schwarz on October 26, 2026 at 5:16 p.m. CEST.

November 2 brings the next test

Vertex Pharmaceuticals is scheduled to report third-quarter 2026 results on November 2, 2026, after the market close, according to The Earnings Madness. The report will follow second-quarter revenue of USD 3.33 billion, which rose 12.50 percent from the prior year, while diluted earnings per share reached USD 4.31.

Stock remains below its yearly high

The Nasdaq quote of USD 512.00 places Vertex Pharmaceuticals within a USD 403.16 to USD 560.25 52-week range as of October 26, 2026. The price is 8.61 percent below the high. Vertex Pharmaceuticals carried a market capitalization of USD 129.8 billion and a price-to-earnings ratio of 29.86.

What does the November date add?

The earnings release will give investors a new operating update before the FDA's November 30, 2026 action date for povetacicept in IgA nephropathy. That date and the latest clinical details were included in a company release carried by Finanznachrichten on October 23, 2026.

Comparison with peers

Vertex Pharmaceuticals: down 2.28 percent, price-to-earnings ratio 29.86, market capitalization USD 129.8 billion

Regeneron Pharmaceuticals: down 0.66 percent, price-to-earnings ratio 19.77, market capitalization USD 82.3 billion

Gilead Sciences: up 1.89 percent, dividend yield 2.00 percent, market capitalization USD 197.1 billion

Dates and valuation frame the stock

The combination of a USD 544.00 consensus target, a November 2 earnings date and the November 30 FDA action date gives Vertex Pharmaceuticals three dated reference points for the next several weeks. The latest quarter provides the operating baseline, with USD 3.33 billion in revenue and USD 1.10 billion in net income.

Price and market context

Vertex Pharmaceuticals was trading at EUR 458.85 at Lang & Schwarz on October 26, 2026 at 5:16 p.m. CEST. The Nasdaq quote stood at USD 512.00 on October 26, 2026 at 12:27 p.m. ET.

The further course of trading is shown by the continuously updated real-time quote of Vertex Pharma stock.